(ARQT) Arcutis Biotherapeutics - Ratings and Ratios

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is a biopharmaceutical company specializing in the development and commercialization of innovative treatments for dermatological conditions. Its lead product, ZORYVE (roflumilast cream), is a topical PDE4 inhibitor approved for the treatment of plaque psoriasis and atopic dermatitis. The companys pipeline includes ARQ-154, a topical foam formulation of roflumilast targeting scalp and body psoriasis, as well as seborrheic dermatitis; ARQ-255, a JAK1 inhibitor for alopecia areata; ARQ-252, a JAK1-selective topical cream under development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for atopic dermatitis. The company, formerly known as Arcutis, Inc., rebranded as Arcutis Biotherapeutics, Inc. in October 2019 and is headquartered in Westlake Village, California. Incorporated in 2016, Arcutis focuses on addressing significant unmet needs in dermatology with its proprietary topical therapeutics.

From a technical standpoint, ARQT has shown recent price strength, with its last price of $14.91 exceeding its 20-day SMA of $14.16. However, the stock is trading below its 50-day SMA of $14.55, indicating potential consolidation. The 200-day SMA of $11.93 reflects longer-term upward momentum. Average trading volume over 20 days is approximately 2.2 million shares, with an ATR of 1.18, suggesting moderate volatility. On the fundamental side, Arcutis has a market cap of $1.75 billion, with a P/S ratio of 8.89, reflecting its revenue growth potential. The P/B ratio of 11.00 indicates premium valuation relative to book value, while the RoE of -88.89 highlights ongoing R&D investments and operating losses typical of a clinical-stage biotech company.